The FDA has allowed Zyn to market its nicotine pouches as lower risk than cigarettes, sparking debate among health experts regarding harm reduction versus youth addiction risks.
Key facts
- •The FDA authorized Zyn to claim lower risks of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis compared to cigarettes.
- •Zyn products have been available in the U.S. for approximately a decade.
- •Philip Morris International states that Zyn's 3 mg pouch delivers a similar amount of nicotine to a single cigarette.
- •In 2025, 4.4% of 12th-graders reported using nicotine pouches within the past 30 days, according to the Monitoring the Future study.
- •Experts warn that the long-term health effects of nicotine pouches remain unknown, as it took over 50 years to fully understand the harms of cigarettes.
The U.S. Food and Drug Administration recently authorized Zyn to advertise that using its nicotine pouches instead of cigarettes reduces the risk of several diseases, including lung cancer and heart disease. The agency stated the decision aims to provide adult users with science-based information to make informed choices. While some experts view the pouches as a safer alternative for current smokers, others express concern over potential youth usage and the lack of long-term health data.
By the numbers
Debate Over Harm Reduction
Proponents of the authorization, including former FDA official Mitch Zeller, argue that nicotine pouches are demonstrably less harmful than burning tobacco leaves. Brian Erkkila, a director at Zyn’s parent company, Philip Morris International, noted that the products helped him quit smoking. However, researchers like Dr. Robert Jackler point out that Zyn is not an FDA-approved smoking cessation tool and argue that its marketing strategies, including the use of flavors and lifestyle imagery, may appeal to non-smokers and adolescents.
Concerns Regarding Youth Usage
Public health experts are increasingly worried about the rise in nicotine pouch use among teenagers. Data from the University of Michigan’s Monitoring the Future study shows that lifetime use among 12th-graders rose from 6.8% in 2024 to 10.0% in 2025. Experts like Bonnie Halpern-Felsher emphasize that nicotine can impact brain development and that there is no health benefit for adolescents to use these products. The Department of Health and Human Services maintains that there is no safe tobacco product and continues to enforce the federal minimum age of 21 for sales.
Advertisement
This article was independently rewritten by ManyPress editorial AI from reporting originally published by NPR Health.
